

IBC COMMITTEE MINUTES

April 23, 2024
Virtual, 9:30 a.m.

MEMBERS PRESENT

Primary:

	Name	College
	**Cassandra (Dawn) Pauling	r/sNA molecules, Biosafety, Animal Containment
X	Selene Nikaido	r/sNA molecules, Plant Expert
	Deb Hudman	Community Representative/Non-Affiliate
X	Rachelle Beattie	Community Representative/Non-Affiliate
X	Cori Brown	Laboratory Facility Representative
X	William Kirby	Laboratory Staff Representative
		UCM Institutional Official (ex-officio)
X	**Kathy Schnakenberg	UCM Research Compliance Officer-Biosafety Adm (ex-officio)

**RCR Training Complete

MEMBERS ABSENT:

MINUTE TAKER: Kathy Schnakenberg

MINUTES

The minutes of _____ were approved with/without revision. Motion to approved made by second- _____. Approved with a vote of 0/0.

PROTOCOLS APPROVED FOLLOWING REVISION

PI Name	Project Title	Date	Action

Business Items

Topic	Discussion	Action	Vote
		N/A	

PROTOCOLS REVIEWED BY COMMITTEE

PI Name and Title of Protocol: *Dawn Pauling, Laboratory Practices of the Wildlife Disease Course BIOL 4412-5412*

Contact Information: pauling@ucmo.edu

Initial Review/ Continuing Review

Summary of Protocol:

This meeting was called to complete the review of the protocol that started at the August 6, 2024 meeting. The review began on the first page of the Registration Form for Infectious Diseases.

Specific Agent:

Associated risks:

Containment process and levels:

Involvement of r/sNA molecules:

Conflicts of Interest:

PI Biosafety Training:

Discussion [for each, indicate if controverted and resolution if controverted]

Issue 1: Registration form for Infectious Agents (non-pathogenic)-Under Safety Measures-Change BSL level from 2 to 1 and mark Safety Googles to match information marked on risk assessment.

Issue 2: Please copy list of BSL-2 agents under the heading Information for Physicians and include in the protocol under Risk Assessment-1. Pathogen Exposure. Add Rabies virus to the list to be consistent with risk assessment sheets.

Issue 3: Please combine risk assessment sheet for *Staphylococcus aureus* and *Staph warneri* using a statement similar to, that *Staph aureus* will be treated as *Staph warneri*. (there are two risk assessment included for *Staph aureus*, one can be deleted).

Issue 4: On risk assessment for *E. coli*-please list the name first so it can be easily seen and then put BSL-1 information in parentheses.

Documentation of Findings

Motion Cori

Second Rachelle

Description of Motion: Motion was made for revisions to be reviewed by William Kirby for final approval.

Vote (For, Against, Abstain): Motion **Passed**/Failed 4-0-0, Total Voting =

Meeting adjourned at _9:31 motion by Will-second by Cori _____

PROTOCOLS REVIEWED BY COMMITTEE

PI Name and Title of Protocol:

Contact Information:

Initial Review/ Continuing Review**Summary of Protocol:****Specific Agent:****Associated risks:****Containment process and levels:****Involvement of r/sNA molecules:****Conflicts of Interest:****PI Biosafety Training:****Discussion** [for each, indicate if controverted and resolution if controverted]Issue 1:Issue 2:Issue 3:**Documentation of Findings****Motion****Second**

Description of Motion:

Vote (For, Against, Abstain): Motion Passed/Failed 0-0-0, Total Voting = 0

Meeting adjourned at _____

PROTOCOLS REVIEWED BY COMMITTEE

PI Name and Title of Protocol:

Contact Information:

Initial Review/ Continuing Review**Summary of Protocol:****Specific Agent:****Associated risks:****Containment process and levels:****Involvement of r/sNA molecules:****Conflicts of Interest:****PI Biosafety Training:****Discussion** [for each, indicate if controverted and resolution if controverted]Issue 1:Issue 2:Issue 3:**Documentation of Findings****Motion****Second**

Description of Motion:

Vote (For, Against, Abstain): Motion Passed/Failed 0-0-0, Total Voting = 0

Meeting adjourned at _____